Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 52
Solid insulin market leadership position in Region Japan &
Korea
tMU
6 4 2
16
14
12
10
Japan & Korea insulin market by segment
Japan & Korea modern and new-generation
insulin volume market shares
Device penetration
-
MI and NGI penetration
CAGR volume¹: 0.5%
Penetration
Novo Nordisk
-
Sanofi
Eli Lilly
CAGR value¹:
(4.4%)
100%
70%
60%
80%
Fast-acting
50%
50%
60%
40%
Premix
30%
40%
20%
26%
24%
Long-acting 20%
10%
0%
0%
May
2013
May
2018
May
2013
Source: IQVIA monthly MAT May, 2018 volume figures
May
2018
8
6
4
2
0
1 CAGR for 5-year period
MI: Modern insulin; NGI: New-generation insulin
Source: IQVIA monthly MAT May, 2018 volume and value (DKK) figures
changing
diabetes®
novo nordiskView entire presentation